Fisetin inhibits vascular endothelial growth factor‑induced angiogenesis in retinoblastoma cells

Wang,Liangjun; Chen,Ning; Cheng,Hongxia

doi:10.3892/ol.2020.11679

Fisetin inhibits vascular endothelial growth factor‑induced angiogenesis in retinoblastoma cells

Authors:
- Liangjun Wang
- Ning Chen
- Hongxia Cheng
View Affiliations

Affiliations: Department of Ophthalmology, Yantai Mountain Hospital, Yantai, Shandong 264001, P.R. China, Department of Ophthalmology, Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China
Published online on: May 28, 2020 https://doi.org/10.3892/ol.2020.11679
Pages: 1239-1244
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fisetin is a small phytochemical molecule with antitumor activity. Angiogenesis is a basic process that occurs during tumor growth and metastasis. The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway is a key regulator of angiogenesis. The aim of the present study was to evaluate whether fisetin affects angiogenesis through the VEGFR pathway. In the present study, Y79 cells were treated with 100 ng/ml VEGF in the presence of fisetin at concentrations of 0, 25, 50 and 100 µM. A Cell Counting Kit‑8 assay was used to detect proliferation and the Transwell and Matrigel assays were used to assess cell migration and invasion, respectively. Reverse transcription‑quantitative polymerase chain reaction analysis was applied to measure the expression level of VEGFR mRNA and western blot analysis was used to measure the protein expression of VEGFR. An immunofluorescence assay was used to detect the expression of VEGFR. Angiogenesis in vitro was assessed by a tube formation assay. The results demonstrated that fisetin significantly inhibited the proliferation of Y79 cells in a time‑ and dose‑dependent manner. Fisetin also inhibited the migration and invasion of Y79 cells in a dose‑dependent manner. Furthermore, fisetin inhibited the expression of VEGFR in Y79 cells in a dose‑dependent manner and tumor angiogenesis in vitro. Thus, fisetin was found to inhibit angiogenesis via inhibition of the VEGF/VEGFR signaling pathway, and could be used as a candidate drug to inhibit angiogenesis in retinoblastoma.

View Figures

View References

1	Shchyogolev AI, Dubova EA and Tumanova UN: Vascularization of hepatocellular carcinoma tissue depends on its differentiation degree. Bull Exp Biol Med. 153:490–494. 2012.(In English, Russian). View Article : Google Scholar : PubMed/NCBI
2	Zeng Y, Yao X, Liu X, He X, LI L, Liu X, Yan Z, Wu J and Fu BM: Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis. J Extracell Vesicles. 8:16298652019. View Article : Google Scholar : PubMed/NCBI
3	Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29 (6 Suppl 16):S15–S18. 2003. View Article : Google Scholar
4	Yan Z, Liu J, Xie L, Liu X and Zeng Y: Role of heparan sulfate in mediating CXCL8-induced endothelial cell migration. PeerJ. 4:e16692016. View Article : Google Scholar : PubMed/NCBI
5	Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H and Hara N: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 60:2169–2177. 2000.PubMed/NCBI
6	Färkkilä A, Anttonen M, Pociuviene J, Leminen A, Butzow R, Heikinheimo M and Unkila-Kallio L: Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. Eur J Endocrinol. 164:115–122. 2011. View Article : Google Scholar : PubMed/NCBI
7	Guo S, Colbert LS, Fuller M, Zhang Y and Gonzalezperez RR: Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 1806:108–121. 2010.PubMed/NCBI
8	Bhat TA and Singh RP: Tumor angiogenesis-a potential target in cancer chemoprevention. Food Chem Toxicol. 46:1334–1345. 2008. View Article : Google Scholar : PubMed/NCBI
9	Jung MH, Sun HL, Ahn EM and You ML: Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis. 30:655–661. 2009. View Article : Google Scholar : PubMed/NCBI
10	Tosetti F, Ferrari N, De Flora S and Albini A: Angiopreventio: Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 16:2–14. 2002. View Article : Google Scholar : PubMed/NCBI
11	Albini A, Noonan DM and Ferrari N: Molecular pathways for cancer angioprevention. Clin Cancer Res. 13:4320–4325. 2007. View Article : Google Scholar : PubMed/NCBI
12	Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wähälä K, Montesano R and Schweigerer L: Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 57:2916–2921. 1997.PubMed/NCBI
13	Paper DH: Natural products as angiogenesis inhibitors. Planta Med. 64:686–695. 1998. View Article : Google Scholar : PubMed/NCBI
14	Adhami VM, Syed DN, Khan N and Mukhtar H: Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol. 84:1277–1281. 2012. View Article : Google Scholar : PubMed/NCBI
15	Park HH, Lee S, Oh JM, Lee MS, Yoon KH, Park BH, Kim JW, Song H and Kim SH: Anti-inflammatory activity of fisetin in human mast cells (HMC-1). Pharmacol Res. 55:31–37. 2007. View Article : Google Scholar : PubMed/NCBI
16	van Acker FA, Schouten O, Haenen GR, van der Vijgh WJ and Bast A: Flavonoids can replace alpha-tocopherol as an antioxidant. FEBS LETT. 473:145–148. 2000. View Article : Google Scholar : PubMed/NCBI
17	Khan N, Asim M, Afaq F, Abu ZM and Mukhtar H: A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 68:8555–8563. 2008. View Article : Google Scholar : PubMed/NCBI
18	Khan N, Afaq F, Syed DN and Mukhtar H: Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis. 29:1049–1056. 2008. View Article : Google Scholar : PubMed/NCBI
19	Liao YC, Shih YW, Chao CH, Lee XY and Chiang TA: Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549. J Agric Food Chem. 57:8933–8941. 2009. View Article : Google Scholar : PubMed/NCBI
20	Suh YS, Afaq F, Johnson JJ and Mukhtar H: A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis. 30:3002009. View Article : Google Scholar : PubMed/NCBI
21	Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM and Yang LL: Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol. 76:351–359. 2002. View Article : Google Scholar : PubMed/NCBI
22	Lim DY and Park JH: Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am J Physiol Gastrointest Liver Physiol. 296:G1060–G1068. 2009. View Article : Google Scholar : PubMed/NCBI
23	Si Y, Liu J, Shen H, Zhang C, Wu Y, Huang Y, Gong Z, Xue J and Liu T: Fisetin decreases TET1 activity and CCNY/CDK16 promoter 5hmC levels to inhibit the proliferation and invasion of renal cancer stem cell. J Cell Mol. 23:1095–1105. 2019. View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Zeng Y, Yao X, Chen L, Yan Z, Liu J, Zhang Y, Feng T, Wu J and Liu X: Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/syndecan-1/TGF-β autocrine loop. Oncotarget. 7:63324–63337. 2016. View Article : Google Scholar : PubMed/NCBI
26	Chen C, Yu DC and Teng LS: Development of anti-tumor drugs targeting VEGF/VEGFR: a progress. Chin J Cancer Biother. 3:291–295,300. 2007.(In Chinese).
27	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
28	Gupta MK and Qin RY: Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol. 9:1144–1155. 2003. View Article : Google Scholar : PubMed/NCBI
29	Cherrington JM, Strawn LM and Shawver LK: New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Adv Cancer Res. 79:1–38. 2000. View Article : Google Scholar : PubMed/NCBI
30	Grimm D, Bauer J and Schoenberger J: Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases. Curr Vasc Pharmacol. 7:347–357. 2009. View Article : Google Scholar : PubMed/NCBI
31	Singh RP, Dhanalakshmi S, Agarwal C and Agarwal R: Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: Implications for angioprevention and antiangiogenic therapy. Oncogene. 24:1188–1202. 2005. View Article : Google Scholar : PubMed/NCBI
32	Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res. 53:3976–3985. 1993.PubMed/NCBI
33	Kraizer Y, Mawasi N, Seagal J, Paizi M, Assy N and Spira G: Vascular endothelial growth factor and angiopoietin in liver regeneration. Biochem Biophys Res Commun. 287:209–215. 2001. View Article : Google Scholar : PubMed/NCBI
34	Masood R, Cai J, Zheng T, Smith DL, Hinton DR and Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 98:19042001. View Article : Google Scholar : PubMed/NCBI
35	Tian X, Song S, Wu J, Meng L, Dong Z and Shou C: Vascular endothelial growth factor: Acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun. 286:505–512. 2001. View Article : Google Scholar : PubMed/NCBI
36	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI